The Phase I trial will recruit approximately 98 healthy volunteers and adults living with atopic dermatitis at a single site ...

The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...

Two of Bambusa’s bispecific antibody candidates for immunological and inflammatory disorders are set to enter the clinic in ...

A year after the FDA rejected its marketing application for CD20xCD3 bispecific antibody odronextamab to treat two common ...

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...

Unlike monoclonal antibodies, bispecific antibodies bind to 2 different antigens simultaneously,[1][1] directing T cells toward cancer cells to exert a cytotoxic killing effect.[1][1] Bispecific ...

With Lava Therapeutics still smoldering from the decision to dump its lead blood cancer drug, the biotech is now laying off ...

Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study 1,2 ; DLBCL-an ...

Therapy timing, patient factors, and emerging combination interventions are guiding treatment decisions in multiple myeloma and lymphoma.

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...

Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary ...

In 2024, we established a strong foundation for what we expect will be a transformational year ahead for Compass,” said Thomas Schuetz, MD, ...